ArticleESMO open2026
Irradiated tumor volume as a predictor of local recurrence and radionecrosis in lung cancer with brain metastases treated with stereotactic radiosurgery.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStereotactic radiosurgery (SRS) is a standard treatment of brain metastases (BM), but it may lead to radionecrosis (RN) or local recurrence (LR). This study evaluates irradiated tumor volume as a predictor of LR and RN in SRS-treated lung cancer patients with BM.
methodsWe retrospectively analyzed 431 lung cancer patients with BM who underwent SRS at Karolinska University Hospital (all-comers, 2009-2020). Associations among irradiated tumor volume and risks of RN, symptomatic RN, and LR at 6 and 12 months were assessed using Cox regression models. Furthermore, we evaluated the diagnostic performance of methionine positron emission tomography-computed tomography (PET-CT) in differentiating RN from LR.
resultsForty patients (9.3%) developed asymptomatic RN, 36 (8.4%) symptomatic RN, and 67 (15.5%) LR. Larger tumor volumes significantly increased RN and LR risks. At 6 months, a volume of 4.75 cm
conclusionLarger irradiated tumor volumes were correlated with increased RN or LR risk. Smaller volumes can lead to RN and LR, not evident at 6 months, but emerging by 12 months after SRS. Methionine PET-CT showed high sensitivity but modest specificity and offered no significant benefit over MRI in differentiating RN from LR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.